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initial 48 patients, BDI data were lacking due to refusals to fill 
out BDI forms or missing data.  Results: Significant and tran-
sient increases in serum S100B were observed in 81.3% of the 
48 patients: 37.5% reached S100B serum levels comparable 
to serum levels found in acute brain injury ( 1 0.20   g/l) and 
43.8% reached mildly elevated S100B serum levels compa-
rable to serum levels found in depressive disorder (0.10–0.20 
  g/l). In 18.7%, no S100B was detected in serum. Using non-
parametric Spearman rank correlation tests, a trend towards 
an association was found between serum S100B and depres-
sive symptoms during the post-MI year (  values between 
0.16 and 0.53) in 27 patients who completed both the S100B 
serum study and the BDI study.  Conclusion: Transiently el-
evated levels of S100B are suggestive of minor acute cerebral 
damage in the first days following MI and associated with 
depressive symptoms in the year following MI. Cerebral 
damage could be an important mechanism in the pathogen-
esis in a subtype of post-MI depression. 
 Copyright © 2009 S. Karger AG, Basel 
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 Abstract 
 Background: Prevalence of depressive symptoms in the 
post-myocardial infarction (MI) period varies from 8 to 30%. 
Cerebral damage after MI, caused by transient ischemia, an 
inflammatory response or both, may contribute to develop-
ment of post-MI depression. S100B is an established protein 
marker of cerebral damage. In a pilot study, the authors as-
sessed whether S100B serum levels are: (1) increased during 
the week after MI, and (2) related to depressive symptoms 
during index hospital admission and the year following MI. 
 Methods: This pilot study is a substudy of the Myocardial 
Infarction and Depression Intervention Trial (MIND-IT). In 48 
patients, serum levels of S100B were available at 1, 2, 3, 4 and 
8 days following MI. Subsequently, in 27 patients, depressive 
symptoms were measured at 0, 3, 6, 9 and 12 months follow-
ing MI with the Beck Depression Inventory (BDI). In 21 of the 
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 Depressive symptoms following myocardial infarc-
tion (MI) have been associated with arrhythmic events 
and an increased risk of cardiac death up to 5 years after 
MI  [1] . In a recent meta-analysis, the odds ratios for all-
cause mortality and cardiac mortality were estimated to 
be 2.38 and 2.59, respectively  [2] . The prevalence of de-
pressive symptoms varies from 8 to 30% depending on 
the assessment method  [3] . 
 Cerebral damage, caused by transient ischemia, an in-
flammatory response or both, may contribute to induc-
tion of post-MI depression. Proinflammatory cytokines, 
including TNF-  , affect blood-brain barrier (BBB) integ-
rity  [4] , and in experimental animal studies MI was as-
sociated with brain damage, most likely through im-
mune-mediated processes  [5] . Brain damage might also 
occur in human MI patients as a result of regular TNF-  
release after MI  [6] . Neuroimaging supports the associa-
tion between subtle cerebral damage and depressive 
symptoms, since in clinically depressed but physically 
healthy patients cerebral white matter lesions (WML) are 
found  [7] . WML in the elderly are associated with a  3- to 
6-times higher risk of depressive symptoms compared to 
patients without WML  [8] . Moreover, it was shown that 
MI and WML are related to each other  [9] .
 Certain proteins in blood circulation may serve as 
markers of central nervous system (CNS) injury. Such an 
established marker is S100B, a calcium-binding protein 
of the S100 family that comprises 21 members. It is pres-
ent in high concentrations in astroglial and oligoden-
droglial cells in the CNS, and is normally not detected in 
peripheral blood. Increased serum S100B levels may in-
dicate glial alterations, either due to brain damage or 
functional secretion of S100B by astrocytes. Disruption 
of the BBB is mandatory to allow for cerebral efflux  [10] . 
Extracellular S100B exerts a dual effect on neurons de-
pending on its concentration, i.e. a pro-survival effect on 
neurons and stimulation of neurite outgrowth at nano-
molar doses and a toxic effect at micromolar doses  [11, 
12] . Circulating S100B has a biological half-life of 25 min 
 [13] . Following acute structural cerebral damage, S100B 
leaks into the bloodstream either directly from damaged 
tissue or indirectly via extra-cellular space. S100B efflux 
due to acute significant cerebral damage leads to a char-
acteristic curve of S100B serum levels. Usually, the high-
est serum levels of S100B are observed 2–4 days after 
acute brain damage and normalize thereafter within 1–3 
weeks  [14] . S100B serum levels reflect S100B Cerebro Spi-
nal Fluid levels  [15] . After acute cerebral injury, serum 
S100B levels  1 0.30   g/l at 48 h have predictive value for 
long-term anxiety  [16] , serum S100B  1 0.50   g/l for per-
sisting neuronal damage  [17] and serum S100B  1 0.70
  g/l for death  [18] . In several (neuro) psychiatric disor-
ders, e.g. melancholic depression, elevation of S100B in 
serum is rather subtle (0.10–0.20   g/l) and over time be-
comes more pronounced  [12, 19–21] .
 S100B can also be found in serum after exercise with 
high cardiac output when activities included repetitive 
jarring movements or contact with the head (running), 
but not after exercise on a stationary bicycle, probably re-
flecting astroglial and/or BBB reaction in the first group 
 [10] .
 However, in certain circumstances S100B is released 
from extra-cerebral tissues, e.g. after trauma, melanoma 
and cardiac surgery  [22–24] . Therefore, it could be argued 
that serum S100B is not solely a marker for cerebral dam-
age, but also a marker of cardiac damage. Fortunately, due 
to the short half-life of S100B and human renal clearance 
of 2 h, release of S100B from different damaged tissues 
leads to different time curves of the (peak) appearance of 
S100B in serum  [14, 25] . This makes it possible to discrim-
inate between different tissue origins of S100B, as was done 
in studies on cardiac surgery with cardiopulmonary by-
pass procedure (CPB) where both cerebral and cardiac 
sources of serum S100B were established  [25] . During CPB, 
S100B was found in special reservoirs for cardiac surgical 
wound blood not contaminated by cerebral blood flow  [26] 
and S100B serum levels measured immediately after car-
diac surgery did correlate with measures of cardiac injury 
and not with neuropsychological outcome, which points to 
a cardiac source of S100B  [27] . However, several other 
studies found a strong positive correlation between in-
creased S100B serum levels and cerebral dysfunction after 
cardiac surgery, pointing to a cerebral origin of S100B in 
CPB  [28–30] . The combination of these results suggested 
that in CPB two different pathophysiological mechanisms 
are responsible for S100B release in serum. Therefore, later 
on, the clinical significance of early and late release of 
S100B after CPB were analyzed separately  [28] . Timing of 
its appearance in the circulation indicated that serum 
S100B has an early peak (immediately at the end of sur-
gery) associated with cardiac damage measured by cre-
atine kinase (CK)  [27] or troponin I  [25] , and a late peak 
(5–48 h after surgery) associated with neurological dys-
function after cardiac surgery  [25, 28] . As far as we know, 
data on the relation between S100B and MI are lacking.
 To validate the hypothesis that cerebral damage may 
occur after MI and may contribute to induction of post-
MI depression we investigated: (1) whether S100B serum 
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levels are increased during the week after MI, (2) the tim-
ing of its appearance in serum to discriminate between 
cardiac and cerebral sources, and (3) whether S100B se-
rum levels in the first week after MI are related to depres-
sive symptoms during hospital admission and the year 
following MI.
 Methods 
 Study Population 
 Data were derived from the Myocardial Infarction and De-
pression Intervention Trial (MIND-IT), a multi-center random-
ized controlled study on the effects of antidepressant therapy for 
post-MI depression on cardiovascular prognosis. Inclusion and 
exclusion criteria have been described previously  [31] . In brief, we 
recruited consecutive patients (September 1999–November 2002) 
hospitalized for acute MI in 10 hospitals across the Netherlands. 
Patients were enrolled if they met WHO MONICA criteria for 
definite MI. The patients for the S100B sub-study were all inpa-
tients at the Coronary Care Unit of Medical Centre, Leeuwarden, 
the Netherlands, 1 of the 10 participating hospitals of the MIND-
IT study. Exclusion criteria were: occurrence of MI while the pa-
tient was hospitalized for another reason, inability to participate 
in study procedures, a disease likely to influence short-term sur-
vival, receiving psychiatric treatment for depression already and 
participation in another clinical trial.
 Procedures 
 Fifty-three consecutive patients (35 men and 18 women; age 
range 47–76 years) entered the S100B study. After written in-
formed consent for participation in the S100B study, blood was 
collected by means of a venous puncture 5 times during the week 
after MI. Blood samples (6 ml) for S100B assays were taken on the 
day of admittance as soon as diagnosis of MI was given, before the 
start of thrombolytic therapy. Time interval between time of ad-
mittance for MI and the first S100B measurement varied between 
1 and 3 h (mean 1.8 h). According to changes in the electrocardio-
graph, reperfusion was obtained 2–12 h after admittance for MI 
(mean 5 h). Information was obtained from clinical records by the 
participating cardiologist. Subsequently, on days 2, 3, 4 and 8, a 
fixed schedule was used and all venous punctures were performed 
at 8 a.m.
 After blood for S100B determination was collected, patients 
were asked to participate in the MIND-IT study. As part of this 
study, patients with MI were screened for depressive symptoms 
during initial hospitalization (0 months) and 3, 6, 9 and 12 months 
after MI with the 21-item Beck Depression Inventory (BDI) ques-
tionnaire, an established method for screening depressive disor-
ders in cardiac patients  [32] . Demographic and medical informa-
tion were obtained from the patients’ medical records ( table 1 ). 
From the 53 patients participating in the S100B study, 30 agreed 
to continue in the MIND-IT study and fill in BDI forms, whereas 
23 refused. After BDI forms were completed, missing data were 
calculated for S100B only (n = 3), BDI only (n = 1) and both S100B 
and BDI (n = 2). Finally, complete data on S100B were available 
for 48 patients. Additionally, for 27 of these 48 patients, complete 
BDI data were available ( fig. 1 ).
 The investigation was carried out in accordance with the latest 
version of the Declaration of Helsinki and the local ethical com-
mittees approved the design of the MIND-IT study. A separate 
informed consent was required by the local ethical committee of 
the Medical Centre of Leeuwarden for the collection of the S100B 
data. All participants were fully informed, and gave written in-
formed consent.
 Infarct Size 
 CK/CK-MB was used as a marker of the presence of MI, not 
for infarct size, as all patients received thrombolytic therapy after 
admission  [33] . Left ventricular ejection fraction (LVEF) was used 
as a more reliable marker of infarct size. Details on the measure-
ment of CK and LVEF were described previously  [31, 34] .
 Biochemistry 
 Heparinized serum samples were centrifuged within 2 h at 
2,300  g ; aliquots were taken and frozen at –20 ° C until analysis. 
Table 1. Baseline and treatment characteristics for S100B
Variable %
Male sex 58.3 (28)
Age >60 years 56.3 (27)
Anterior MI 33.3 (16)
Cardiac history (MI, PCI, CABG) 12.5 (6)
CK-MB (mean 8 SD), U/l 1978164
Peak CK (mean 8 SD), U/l 2,08081,650
LVEF <45% 20.9 (10)




Calcium antagonists 8.3 (4)
Statins 12.5 (6)
ACE inhibitors 8.3 (4)











Calcium antagonists 35.4 (17)
Statins 77.1 (37)
ACE inhibitors 27.1 (13)
Values are percentages with the numbers of subjects given
in parentheses, unless otherwise indicated. PCI = Percutaneous 
coronary intervention; CABG = coronary artery bypass graft 
 surgery; LVEF = left ventricular ejection fraction; ACE = angio-
tensin-converting enzyme.
 Tulner et al. 
 
Neuropsychobiology 2009;59:87–95 90
S100B was determined with an immunofluorometric sandwich 
assay using a monoclonal anti-S100B chain antibody (LIA-mat R 
Sangtec Kit and Magic Little Analyzer 2, version 4.0; Sangtec, 
Bromma, Sweden). The Sangtec 100 LIA immunoluminometric 
assay uses tubes coated with 2 monoclonal antibodies as solid 
phase, and a monoclonal antibody for detection. The assay mea-
sures concentrations of S100B protein over the range of 0.02–20 
  g/l. Measurements were performed according to the instruc-
tions of the manufacturer. Details about linearity, a description of 
the analytical technique, the accuracy and precision, and limit of 
quantification of the kit were described earlier  [35] . 
 The assay’s threshold for detecting S100B is 0.02   g/l. To min-
imize inter-assay variations, S100B was determined after all sam-
ples were collected.
 Statistical Analysis 
 No sample size calculation was performed due to the explor-
atory nature of the trial. S100B data are expressed as medians and 
interquartile ranges, which are less affected by outliers in a small 
sample than means and standard deviations. Missing S100B data 
(6.7%) and missing data on the BDI (4.4%) were estimated by 
means of 2-way imputation  [36] . The method was only used for 
patients with 2 or fewer missing values. As a consequence, 5 pa-
tients were excluded from further analyses on S100B, and 3 pa-
tients were excluded from analyses involving the BDI ( fig. 1 ). 
Brain damage was expressed as both S100B peak value between 
days 2 and 4, and S100B area under the curve (AUC). AUC was 
calculated for each participant by integrating simple linear func-
tions, which were set up using S100B at days 1, 2, 3, 4 and 8. The 
course of S100B during the first week after MI was evaluated with 
non-parametric pairwise comparisons between S100B at day 1, 
S100B peak value (days 2–4) and S100B at day 8 (Wilcoxon signed-
rank test). 
 The relationships of S100B peak values and S100B AUC with 
BDI scores and LVEF, respectively, as a measures of MI severity, 
were evaluated with non-parametric Spearman rank correlation 
tests (  ). Given the small sample size,   was set at 0.10 to increase 
statistical power.
 With regard to the peak levels of serum S100B, 3 subcategories 
of patients were made in order to allow comparison (especially in 
the low range) with (neuro)psychiatric diseases in which elevated 
S100B concentrations are known to occur and are related to clin-
ical symptoms. The first group was defined as having no S100B 
serum levels above 0.10   g/l, which is comparable with healthy 
controls  [37] . The second group was defined according to mildly 
elevated S100B levels between 0.10 and 0.20   g/l, comparable 
with levels found in melancholic depression  [21] . The third group 
was defined according to serum S100B levels  1 0.20   g/l mea-
sured in various degrees of acute neurological pathology ranging 
from minor traumatic head injury  [38] to stroke with unfavorable 
outcomes  [10, 14, 17, 23, 28, 30, 38] .
 Results 
 Subjects (n = 30) who filled out a BDI did not differ 
from those who refused (n = 23) with respect to age, gen-
der, co-morbidity, renal function, MI severity (LVEF) or 
S100B values.
 Serum S100B Levels and Time Course 
 Non-parametric pairwise comparisons revealed sig-
nificant differences for the sample as a whole between 
S100B at day 1 and S100B peak value (Z = –4.01; p  ! 0.001). 
No significant difference was found between S100B at day 
1 and S100B at day 8 (Z = –1.14; p = 0.25).  Figure 2 shows 
the temporal pattern of the median S100B levels and in-
53Total number of 
patients in S100B study 
Missing S100B data 5










and/or BDI data 
3





 Fig. 1. Flow chart of patients in the S100B 
and subsequently the MIND-IT study. 
Missing data: S100B only (n = 3), BDI only 
(n = 1) and both S100B and BDI (n = 2). 
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terquartile range of the whole group (n = 48). Nine pa-
tients (18.7%) had no serum S100B levels above 0.10   g/l. 
The second group of 21 patients (43.8%) had  mildly ele-
vated serum S100B levels between 0.10 and 0.20   g/l, 
comparable with levels found in melancholic depression 
 [21] . In the third group of 18 patients (37.5%), serum 
S100B levels were significantly elevated and reached lev-
els  1 0.20   g/l as measured in acute neurological pathol-
ogy. Five of these reached values analogous to values seen 
in the range of severe cerebral pathology, e.g. stroke 
( 1 0.35   g/l;  fig. 3 ).
 Serum S100B and Infarct Size 
 S100B peak value (  = –0.14; p = 0.49) and S100B AUC 
(  = 0.03; p = 0.90) were not associated with LVEF (n = 
48).
 Serum S100B and Depressive Symptoms 
 Depressive symptoms assessed at initial hospitaliza-
tion were not related to serum S100B peak value and se-
rum S100B AUC ( fig. 3 ; n = 27). However, serum S100B 
peak values and serum S100B AUC were both associated 
with the BDI score of depressive symptoms at follow-up 
( fig. 3 ). As shown in  table 2 , a consistent pattern of sig-
nificant correlations and trends was found for depressive 
symptoms assessed at 3, 6, 9 and 12 months after MI (n = 
27). 
 Discussion 
 This pilot study is the first to report that S100B serum 
levels may be increased in the first week after MI in a time 
and peak pattern comparable with serum S100B release 
after acute cerebral damage ( fig. 2 ). Moreover, a trend to-
wards an association was found between serum S100B 
levels and depressive symptoms during  the first year after 
MI, especially at the later measurement points 3–12 
months after MI ( table 2 ). S100B serum levels were not 
associated with infarct size as derived from LVEF. These 
data indicate that cerebral damage may play a role in the 
development of post-MI depression. 
 Although we measured plasma CK/CK-MB, it was not 
used as a marker of infarct size as early thrombolytic 
therapy is a confounder in this situation  [33] . Therefore, 
we preferred LVEF as a marker for infarct size.
 The results are consistent with previous studies on the 
association between the late increase in S100B serum lev-
els and cognitive/neurological dysfunction after CPB  [25, 
28] . In late release, defined as the first 5–48 h after CPB, 
S100B serum contamination from cardiac sources is pre-
sumed to be insignificant  [24, 28] . Our study results are 
also in line with the observation that heightened S100B 
serum levels ( 1 0.30   g/l) 48 h after CPB might predict 
long-term (3–6 years) anxiety  [16] demonstrating that a 
single cardiac event might result in long lasting psychiat-
ric symptoms. In light of these studies it is not surprising 
that another single cardiac event as MI may result in 
long-lasting depressive symptoms.
 As the relation between S100B serum levels and MI is 
unknown, the question to be considered here is whether 
the S100B serum levels after MI have a cerebral, cardiac 
or mixed origin. Several arguments favor a predominant-
0
























 Fig. 2. Time course of median S100B serum levels of the whole 
sample following MI (n = 48). The error bars represent the inter-
quartile range.  
Table 2. Spearman’s  correlation coefficients for S100B (peak val-
ue and AUC) and depressive symptoms at baseline and follow-
up
Depressive symptoms S100B peak value S100B AUC
First week after MI 0.07 0.16
3-month follow-up 0.47** 0.34*
6-month follow-up 0.30 0.23
9-month follow-up 0.53*** 0.34*
12-month follow-up 0.36* 0.16
* p < 0.10; ** p < 0.05; *** p < 0.01.
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ly cerebral origin of the S100B serum levels we found in 
this pilot study. The isolated ischemic rat heart releases 
S100B, but only for a maximum of 60 min after myocar-
dial ischemia  [39] . As yet no data are available in man. 
Considering the short biological half-life of S100B of 25 
min and human renal clearance of 2 h  [13] the supposed 
early but transient cardiac release of S100B due to MI will 
probably only last from some minutes to an hour. This 
rise will probably remain unnoticed when examining se-
rum samples taken at least several hours following MI, as 
was the case in this study. As the average time between 
hospital admittance for MI and the first serum S100B 
measurement point was 1.8 h, and time between admit-
tance for MI and reperfusion 5 h, we cannot completely 
rule out that cardiac S100B added to the amount of serum 
S100B, especially in the serum S100B measurements on 
day 1. For the measurements of serum S100B on days 2–8 
this is highly unlikely, considering the half-life of 25 min. 
Moreover, we did not find any association between LVEF 
and S100B serum levels, which also points to an extra-
cardiac origin of S100B. 
 In addition, the cerebral origin of serum S100B is 
strongly backed up by the time course, with a peak of me-
dian S100B serum levels on days 2–3 after MI ( fig. 2 ). The 
pattern is the same as seen after primary acute cerebral 
injury  [14] and also corresponds with the time pattern of 
late-release serum S100B associated with cerebral dam-
age after CPB  [25, 28] . The observed S100B serum levels 
( fig. 3 ) are also comparable to S100B levels found in vari-
ous neurological and psychiatric study populations.
 In order to estimate the clinical significance of the 
measured S100B serum levels, we divided our study pop-
ulation into 3 subgroups. This made comparison possible 
with previous study populations in which a relation was 
0
0.2
0 5 10 15 20







































Mild S100B elevations as found in melancholic depression
Severe S100B elevations as found in acute neurological pathology
BDI score at 3-month follow-up Fig. 3. Scatter plots: relation between se-
rum S100B peak value (  g/l) and BDI 
score. 
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established between serum S100B and the clinical disease 
examined. The first group (18.7%) had no S100B eleva-
tion at all, therefore the conclusion that MI does not au-
tomatically lead to late (5–48 h) release of serum S100B is 
justified. The second group (43.8%) was defined accord-
ing to S100B levels found in depressive disorder (0.10–
0.20   g/l)  [21] . The third group (37.5%) had levels  1 0.20 
  g/l that can be found in various forms of cerebral dam-
age ranging from minor traumatic head injury to stroke 
 [10, 14, 17, 23, 28, 30, 38] . This last comparison adds to the 
preliminary conclusion that the serum S100B levels we 
found might have clinical relevance. 
 The variation in S100B levels between the 3 groups is 
probably due to individual variation in cerebral vulner-
ability for changes after MI, which is consistent with the 
observation that patients with a previous history of stroke 
or transient ischemic attack had higher levels of S100B 
directly after CPB than those who did not  [28] . We pre-
sume that the incidental high serum S100B levels  1 0.35 
  g/l in the range of serious neurological damage  [10, 30] 
may point to small non-progressive brain lesions, formed 
shortly before blood was collected as none of the patients 
experienced physical neurological symptoms. Consistent 
with the latter is that in a serum S100B serial measure-
ment study of head trauma, values of 0.9   g/l were mea-
sured with a rapid decline to 0.2–0.4   g/l during the first 
12 h after the trauma  [40] . None of the patients in our 
study had persistently high serum S100B values.
 The clinical relevance of glial protein S100B in depres-
sive disorder has not yet been established. Histopatho-
logical postmortem studies showed consistent reductions 
in glial cell density in prefrontal brain regions of depres-
sive patients  [41] . A relation between elevated serum 
S100B levels and melancholic major depression (a sub-
type of depressive disorder) was established in physically 
healthy patients  [19] . It was replicated for other but not all 
types of depressive disorder  [19, 21] . In case of association 
between depressive disorder and S100B serum levels, the 
levels were consistently between 0.05 and 0.2   g/l  [21] .
 Antidepressant drugs influence secretion of S100B by 
astrocytes via the serotonergic system  [42] . S100B may 
induce neurogenesis  [43] that is required for behavioral 
effects of antidepressants  [44] . Four treatment studies 
showed that S100B decreases after successful antidepres-
sant treatment  [20, 21, 45, 46] . Patients with increased 
S100B levels had a better therapeutic response than those 
with normal S100B levels  [46] . However, the effect sizes 
differ  [21] , and this may have its origin in the fact that 
depressive disorder is a heterogeneous group of psychiat-
ric disorders with different neurobiological and psycho-
logical characteristics. It is a spectrum disorder with at 
one end characteristic predominant psychological symp-
toms, possibly reflecting only a ‘psychological’ reaction 
to stressful circumstances including a life-threatening 
disease; the other end is characterized by severe somatic 
symptoms combined with a typical cognitive profile, and 
related to somatic diseases such as brain damage, MI and 
severe LV dysfunction in which it is difficult to assess 
whether the depression is a ‘biological’ consequence of 
the illness itself or not  [8, 47] .
 The MIND-IT study provided evidence for the same 
heterogeneity in post-MI depression  [47] . Moreover, it 
was found that a significant number of patients were de-
pressed before MI, and impaired cardiovascular progno-
sis and heightened mortality were found only in patients 
with incident post-MI depression. Incident post-MI de-
pression might be a depressive subtype that is a patho-
physiological consequence of cardiovascular illness itself 
 [48] .
 The association of elevated S100B levels in the first 
week after MI with depressive symptoms at 3- to 12-
month follow-up indicates that de novo cerebral damage 
may contribute to the development of post-MI depres-
sion. This is also indicative of a specific (biological) sub-
type of post-MI depression, and in line with earlier re-
ports on cardiac events and induction of psychopathol-
ogy  [16] . Although there seems to be a connection, the 
small number of patients causes a statistical weakness of 
association between S100B and depressive symptoms. 
Large-scale studies are necessary to gather more in-depth 
insight into the connection between S100B levels and de-
pressive symptoms.
 As different subtypes of post-MI depression have a dif-
ferent response to treatment and non-response is associ-
ated with more cardiac events  [48] , it is important to ob-
tain knowledge about possible mechanisms in the asso-
ciation between depressive symptoms and MI in the 
several subtypes of post-MI depression in order to de-
velop prophylactic and therapeutic regimens, both in 
terms of quality of life and prognosis. 
 Given the dual (survival and toxic) effect on neurons 
and its wide variety of intra- and extra-cellular functions, 
it remains to be proven if the increase in S100B serum 
concentration in our study is due to substantial destruc-
tion of CNS tissue or to an active release of S100B from 
intact astrocytes attempting to repair neuronal damage.
 The present findings need to be interpreted with cau-
tion, given the small number of subjects, the absence of 
neuropsychological tests to assess cognitive impairment 
and the lack of inflammatory data. Nor do we exclude the 
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